# Surge Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/surge-therapeutics

- Industry: Biotechnology
- Headquarters: Cambridge, US
- Website: www.surgetx.com
- Total disclosed funding: $53M
- Latest round: Series B (May 19, 2023)
- Investors on record: 10

## About

Founded in 2021 by Michael Goldberg (CEO), and based in Massachusetts, US, Surge Therapeutics is a biotechnology research platform that is developing a therapeutic medication that helps cancer patients to live longer lives by preventing post-surgical cancer recurrence. In July 2023, Surge raised USD 32 million in series B funding led by Bioluminescence Ventures, with participation from KdT Ventures, Piedmont Capital Investments, 8VC, Alumni Ventures, Camford Capital, Cancer Research Institute, Intuitive Ventures, Khosla Ventures, and Pitango Venture Capital.

The company provides the SURGERx platform, which is intended to increase the efficacy and safety of immunotherapy medication provided to cancer patients following tumor removal surgery. To improve patient survival results, the firm provides an injectable biodegradable hydrogel that allows for the extended, localized release of cancer immunotherapy at the site of surgical tumor removal.

## Funding rounds

- Series B, May 19, 2023, $32M — Pitango, Khosla Ventures, Alumni Ventures Group, 8VC, KdT Ventures, Intuitive Ventures, Camford, Cancer Research Institute, Piedmont Capital Investments, Bioluminescence Ventures
- Series A, Nov 23, 2020, $21M — Pitango, Khosla Ventures, Alumni Ventures Group, 8VC, Intuitive Ventures, Camford, Cancer Research Institute

## Investors

- Pitango (https://capitalatlas.ai/funds/pitango) — Series A, Series B
- Khosla Ventures (https://capitalatlas.ai/funds/khosla-ventures) — Series A, Series B
- Alumni Ventures Group (https://capitalatlas.ai/funds/alumni-ventures-group) — Series A, Series B
- 8VC (https://capitalatlas.ai/funds/8vc) — Series A, Series B
- Intuitive Ventures (https://capitalatlas.ai/funds/intuitive-ventures) — Series A, Series B
- Camford (https://capitalatlas.ai/funds/camford) — Series A, Series B
- Cancer Research Institute — Series A, Series B
- KdT Ventures (https://capitalatlas.ai/funds/kdt-ventures) — Series B
- Piedmont Capital Investments (https://capitalatlas.ai/funds/piedmont-capital-investments) — Series B
- Bioluminescence Ventures (https://capitalatlas.ai/funds/bioluminescence-ventures) — Series B